Roll-over study in patients with TSC and refractory seizures who are judged by the Investigator to benefit from continued treatment with everolimus after completion of study CRAD001M2304

To evaluate the long term safety data with everolimus treatment i.e adverse events (AEs) and serious adverse events (SAEs).